Biotech Stocks Facing FDA Decision In January 2022

2 / 8
Xeris Biopharma
Xeris Biopharma

The FDA decision on Xeris Biopharma Holdings Inc.s (XERS) Recorlev, proposed for the treatment of endogenous Cushing’s syndrome, is expected on January 1, 2022.

Recorlev came under Xeris Biopharma’s fold when the company acquired Strongbridge Biopharma in October of this year.

Cushing's syndrome, a rare endocrine disorder, develops either when the body produces too much glucocorticoid (endogenous) or due to taking glucocorticoid medicines for a long time (exogenous). This condition is characterized by rapid weight gain, especially in the trunk and face, stretch marks and bruises, bone loss, muscle weakness, and changes in mood.

The currently approved drugs for endogenous Cushing’s syndrome include Corcept Therapeutics' Korlym and Novartis' Isturisa and Signifor.

If approved, Recorlev has the potential to be a $250 million to $350 million annual peak sales product in the U.S. alone, according to the company.

XERS closed Thursday’s (Dec.23, 2021) trading at $2.59, up 6.58%.